Seiter will be responsible for the finance, treasury, and accounting functions of the company.
Seiter has over two decades of experience in the healthcare industry. He most recently served as CFO of Millendo Therapeutics.
He previously spent 23 years in investment banking, and also served in the US Navy as a nuclear submarine officer for five years.
Trevi is focused on developing the synthetic opiod Nalbuphine ER for chronic pruritic conditions. The company is pursuing several pruritic conditions, including pruritis nodularis, for which there is no approved treatment in the US or EU.
Nalbuphine ER is an oral extended release synthetic opioid with a dual mechanism of action, mu receptor antagonist and kappa receptor agonist, both of which have been shown in research to be effective in abolishing itch.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval